SeraCare Life Sciences has entered into a strategic agreement with biotechnology firm ViveBio to jointly market and sell their combined technologies into the in vitro diagnostic (IVD) development market.
ViveBio develops and markets preanalytic products based upon ViveST technology. Products enabled with ViveST permit sample collection, transport and storage in a dried and shelf stable format.
SeraCare precision medicine business unit vice-president Trevor Brown said: "With the recent advances in breakthrough drug therapies for HIV, HCV and other virologic diseases, more of our key IVD customers are developing assays for the major global initiatives seeking to identify and subsequently treat those infected with the proper therapies.
"Combining SeraCare’s deep expertise in supporting advanced diagnostics development with ViveBio’s groundbreaking ViveST technology will give diagnostics developers economical solutions to specimen collection and stabilization, coupled with QC tools that will help improve the diagnostic reach and performance of these tests."
SeraCare develops and markets a broad range of products, technologies and services, which enhances the development and commercial adoption of diagnostic assay development programs, including a wide range of natural and engineered infectious disease materials, in-kit controls and third party reference materials.
The firm produces products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.